

The major function and primary strength of the AC is provision of reliable technically robust panels of assays for environmental contaminants and markers of exposure or behavior that are of interest to UK-CARES researchers (see **Tables 1-3**). Consistent with the themes of the Center, these include methods to support measurements of environmental chemical or biomarkers in the areas of water, air quality, and emerging threats. Unless otherwise indicated, limits of quantitation (LOQ) for organic contaminants are experimentally determined and represent the lowest concentration of analyte where the relative uncertainty for a single measurement is within  $\pm 20\%$  determined using 3-5 injections of a range of concentrations of the analyte at, above, and below the estimated limit of quantitation. The methods listed below generally employ mass labeled internal standards for quantitation. In some cases where these are not available for all the analytes internal standards and surrogates are employed. ICP-MS-based methods use either rare element internal standards or isotope-dilution techniques and limits of quantitation are three times the method detection limit (or 9 standard deviations of the blank intensity). Methods generally employ in batch continuous calibration verification protocols and generally involve measurement of quantifier and qualifier ions. The LOQ are determined for the quantifier ion. Qualifier ions are generally less intense and may not be measurable at or close to the limit of quantitation. Quality assurance approaches are discussed separately.

**Table 1. Environmental contaminant analytical panels.**

| Analytical Panel   | Method                         | Matrices, vol.                            | LOD, LOQ (range)   | Notes   |
|--|--------------------------------|---|--|---|
| <b>Per and Poly Fluorinated Substances:</b><br>Short-chain: PFBS, GenX, 4:2 FTS,<br>Long-chain, PFNA, PFOA, PFHxS,<br>PFHpA, PFOS: Surrogates, 4:2 FTSL,<br>PFOAL, PFNAL, PFOSL  | UHPLC<br>ESI<br>MS/MS<br>(MRM) | Plasma,<br>Serum, Urine<br><br>50 $\mu$ l | 0.05-0.2 ng/ml<br><br>(0.05-10 ng/ml)                                      | Panel includes multiple legacy and newer/GenX compounds. We continue to add new compounds to this assay and will transition the methods to utilize the TSQ Altis Mass spectrometer. |
| <b>Phthalates and metabolites:</b><br>monomethyl phthalate (MMP), monoethyl phthalate (MEP), mono-n-butyl phthalate (MBP), MEHP, mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), monobenzyl phthalate (MBzP) and mono-n-octyl phthalate (MOP), | UHPLC<br>ESI<br>MS/MS<br>(MRM) | Plasma/Serum<br>Urine<br><br>50 $\mu$ l   | 0.1 ng/ml<br><br>(1-1000 ng/ml)  | Assay is validated for MEP and MBP with additional metabolites to be added.   |
| <b>Environmental Phenols</b><br>4-t-Octylphenol<br>Benzophenone-3 (Oxybenzone)<br>Bisphenol A (BPA)<br>o-Phenylphenol<br>Parabens<br>Triclocarban<br>Triclosan   | UHPLC<br>ESI<br>MS/MS<br>(MRM) | Plasma Serum<br>Urine<br><br>50 $\mu$ l   | 0.1 ng/ml (urine)<br>(1-1000 ng/ml)  | BPA measurements have been used for studies with preclinical models and clinical samples.   |
| <b>Polychlorinated biphenols-</b> selected individual congeners  | GC-MS<br>(SIM)                 | Plasma,<br>Serum, 1ml                     | LOQ: 0.01-0.05 ng/ml (ECD)<br>LOQ: 0.05-0.1 ng/ml SIM MS<br>(0.05-50ng/ml) | MS method is complementary to ECD method for identification of PCB congeners  |

|   |                               |  |  |   |
|---|-------------------------------|--|--|---|
| <b>Polychlorinated Biphenyls-</b><br><br>Mixture: Includes dioxin like and non-dioxin like congeners, components of commercial Arochlor preparations.   | GC-MS/MS<br><br>(SRM)         | Plasma,<br>Serum, 1ml                        | LOQ: 0.03-0.07pg/ml<br>(non ortho PCBs)<br><br>LOQ: 1-3 pg/ml (mono<br>ortho PCBs)<br><br>LOQ:2-7 pg/ml non<br>dioxin like PCBs<br>(LOQ to ~ 1ng/ml) | 209 different PCB congeners can be measured using this method based on chromatographic separation and SRM                     |
| <b>Polychlorinated Dibenzofurans</b><br><br><b>PCDFs</b><br><br>2,3,7,8-TCDF, 1,2,3,7,8-PeCDF<br><br>2,3,4,7,8-PeCDF, 1,2,3,4,7,8-HxCDF<br><br>1,2,3,6,7,8-HxCDF,2,3,4,6,7,8-HxCDF<br><br>1,2,3,7,8,9-HxCDF,1,2,3,4,6,7,8-HpCDF,<br>1,2,3,4,7,8,9-HpCDF | GC-MS/MS                      | Plasma,<br>Serum, 1ml                        | LOQs: 0.01-0.05 pg/ $\mu$ l<br><br>(LOQ to ~ 1 ng/ml)  | Method validated for preclinical samples  |
| <b>Polychlorinated dibenzo-p-dioxins</b><br><br>2,3,7,8-TCDD, 1,2,3,7,8-PeCDD<br><br>1,2,3,4,7,8-HxCDD, 1,2,3,6,7,8-HxCDD<br><br>1,2,3,7,8,9-HxCDD,1,2,3,4,6,7,8-HpCDD  | GC-MS/MS                      | Plasma,<br>Serum, 1ml                        | LOQs :0.2-5 pg/ml<br>(LOQ-   | Method validated for preclinical samples  |
| <b>Flame Retardants</b><br><br><b>Organophosphorous compounds :</b><br><br>tris (1,3-dichloropropyl) phosphate:<br>TDCPP, triphenyl phoephate (TPP) Bis<br>(1,3-dichloropropyl) phosphate (BDCPP)<br>and diphenyl phosphate (DPP)                       | UHPLC<br><br>ESI<br><br>MS/MS | Plasma,<br>tissues, urine                    | LOQ: 1 pg/ml   | Method validated for measurement of metabolites (BDCPP and DPP) in preclinical studies  |
| <b>Total trace element concentrations</b>   | ICP-MS or ICP-OES             | Most biological and environmental matrices   | LOQs: matrix and element-dependent, as low as 0.1 pg/L   | Majority of elements in periodic table can be analyzed  |
| As, Hg, and Se speciation   | HPLC<br><br>ICP-MS            | Tissues, environmental samples, blood, urine | LOQs: matrix and element-dependent, as low as 1 ng/L   | Validated for environmental and biological samples. Needs work to be validated for clinical studies                           |
| Spatial analysis of trace elements  | LA-ICP-MS                     | Solid samples                                | LOQs: matrix and element-dependent, as low as 0.1 ug/g   | Standard reference materials for most biological matrices are not available for this technique. Results are semi-quantitative |
| Nanoparticle number, size and composition   | sp-ICP-MS                     | Liquid samples and tissue digests            | LOQs- limits are element specific. As small as 5 nm diameter and mass concentrations as low as 1 fg/L  | Highly experimental technique but gaining widespread use for quantification of nanoparticle exposure                          |

|  |  |                |             |   |
|--|--|----------------|-------------|---|
| <b>Trihalomethanes and haloacetonitriles:</b><br>chloroform, bromodichloromethane<br>chlorodibromomethane, bromoform<br>bromomethane, dichloromethane,<br>dichloroacetonitrile, trichloroacetonitrile,<br>bromoacetonitrile, dibromoacetonitrile | GC-dual ECD<br>after liquid/liquid<br>extraction | Drinking water | LOQ: 1 ug/L | Disinfection byproducts- EPA<br>method 551.1 <sup>18</sup> . validated for<br>drinking water samples.<br>Simultaneous analysis on<br>dissimilar columns provides<br>confirmation. |
|--|--|----------------|-------------|---|

**Table 2. Biomarkers of tobacco and opiates.**

| Analytical Panel  | Method            | Matrices                        | LOQ (range)                       | Notes  |
|---|-------------------|---------------------------------|-----------------------------------|--|
| <b>Nicotine, Cotinine, trans 3 OH cotinine &amp; glucuronide metabolites</b>  | HPLC ESI<br>MS/MS | Plasma, serum,<br>urine 0.5-1ml | 0.015 ng/ml (0.015-10<br>ng/ml)   | Biomarkers of tobacco smoking<br>and e cigarette use |
| <b>Tobacco specific Nitrosamines:</b><br>4-(methylnitrosamino)-1-(3-pyridyl)-1-<br>butanone (NNK) and <i>N'</i> -nitrosonornicotine<br>(NNN)4-(methylnitrosamino)-1-(3-pyridyl)-<br>1-butanol (NNAL) & glucuronide<br>metabolites | HPLC ESI<br>MS/MS | Urine 1ml                       | 20 pg/ml (20pg/ml-10<br>ng/ml)    | Biomarkers of tobacco smoking                        |
| <b>Common Opiates:</b> codeine, fentanyl,<br>morphine, heroin, hydrocodone,<br>hydromorphone, oxycodone,<br>oxymorphone   | HPLC ESI<br>MS/MS | Plasma, serum<br>0.5 ml         | 0.15-0.4 ng/ml<br>(0.4-150 ng/ml) | Narcotic Analgesics, drugs of<br>abuse               |

**Table 3. Nutritional biomarkers.**

| Analytical Panel   | Method                         | Matrices                | LOQ (range)                        | Notes  |
|--|--------------------------------|-------------------------|------------------------------------|--|
| <b>Trimethylamine N-Oxide (TMAO)</b>   | HPLC ESI<br>MS/MS              | Plasma, Serum           | 0.05 $\mu$ M<br>(0.05-200 $\mu$ M) | Biomarker of red meat/fish, eggs<br>consumption                                      |
| <b>Odd/Branched Chain Fatty Acids<br/>(method also measures common fatty<br/>acids)</b>  | GC-MS,<br>GC-MS/MS<br>LC-MS/MS | Plasma, Serum<br>0.2 ml | ~1 ppm (1-<br>10,000ppm)           | Biomarkers of dairy food and<br>fibers (LCMS method uses<br>chemical derivatization) |
| <b>Endogenous sterols and plant<br/>phytosterols</b> Plant sterols: beta<br>sitosterol, cholestenol campesterol<br><br>Endogenous cholesterol precursors:<br>desmosterol, lathosterol, cholesterol | GC-MS/MS                       | Plasma, Serum<br>0.2 ml |                                    | Biomarkers of endogenous<br>cholesterol synthesis and dietary<br>cholesterol intake  |
| <b>Isoprostanes</b><br>F2-isoprostane (15-F2t-IsoP) and<br>prostaglandin F2 alpha (PGF2 alpha)   | HPLC ESI<br>MS/MS              | Urine (1ml)             | 0.05 ng/mL (0.05-10<br>ng/ml)      | Biomarkers of systemic oxidative<br>stress   |